Regeneron Pharmaceuticals, Inc. REGN
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About REGN
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Regeneron Pharmaceuticals, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of medicines for serious diseases. The company operates primarily in the biotechnology and biopharmaceutical industries, with therapeutic areas spanning ophthalmology, immunology, oncology, cardiovascular disease, infectious diseases, hematologic conditions, and rare genetic disorders. Regeneron generates revenue through sales of proprietary medicines, collaborative commercialization agreements, and research and development partnerships. Key revenue drivers have included EYLEA for retinal diseases, Dupixent through its collaboration with Sanofi, and oncology products such as Libtayo.
The company was founded in 1988 by Leonard Schleifer and scientists associated with advances in neurobiology and molecular genetics research. Regeneron evolved from an early-stage research biotechnology firm into a large-cap global biopharmaceutical company through sustained investment in antibody technologies, genetics-based drug discovery, and vertically integrated biologics manufacturing. The company is widely recognized for its proprietary VelociSuite technologies, which support rapid antibody discovery and genetic target validation, contributing to its competitive position within the biotechnology sector.
Business Operations
Regeneron operates through integrated research, clinical development, manufacturing, and commercial operations. The company’s core business activities include the development and commercialization of monoclonal antibodies, biologic medicines, and genetically informed therapeutic candidates. Major commercial products include EYLEA and EYLEA HD for retinal diseases, Dupixent for inflammatory diseases under a collaboration with Sanofi, Libtayo for oncology indications, Kevzara for rheumatoid arthritis and inflammatory conditions, and Praluent for cholesterol management. Revenue is generated through direct product sales, profit-sharing arrangements, licensing agreements, and collaboration revenue from strategic partners.
The company maintains significant operations in the United States while expanding internationally through commercial partnerships and regional infrastructure. Regeneron controls substantial biologics manufacturing capabilities in New York State and has invested heavily in research campuses and production facilities to support large-scale biologic manufacturing. Important partnerships include collaborations with Sanofi and Bayer, particularly for Dupixent and EYLEA commercialization outside certain markets. The company also maintains research alliances and clinical partnerships across oncology, immunology, and genetic medicine development programs.
Strategic Position & Investments
Regeneron’s strategic direction centers on genetics-driven drug discovery, expansion of immunology and oncology franchises, and continued investment in proprietary antibody and genomic technologies. The company has consistently increased research and development spending to support broad clinical pipelines across autoimmune disease, cancer therapeutics, obesity-related conditions, ophthalmology, and rare diseases. Regeneron has emphasized the use of human genetics databases and artificial intelligence-supported discovery tools to improve target identification and therapeutic development efficiency.
Major strategic investments have included expansion of manufacturing infrastructure, increased ownership and development of proprietary technologies, and acquisitions aimed at strengthening genomic and oncology capabilities. Regeneron acquired Checkmate Pharmaceuticals to expand its immuno-oncology portfolio and has invested in large-scale genetics initiatives through the Regeneron Genetics Center. The company also maintains strategic collaborations with Sanofi and Bayer, which provide international commercialization scale and shared development resources. Emerging focus areas include next-generation oncology antibodies, gene-silencing approaches, and advanced immunology therapies.
Geographic Footprint
Regeneron is headquartered in Tarrytown, New York, and maintains major operational facilities across the United States, including research and manufacturing sites in New York and other states. The company’s medicines are marketed in multiple global regions through direct operations and collaboration agreements, particularly across North America, Europe, Asia-Pacific, and selected markets in Latin America and the Middle East.
Internationally, Regeneron’s commercial reach is significantly supported through partnerships with Bayer and Sanofi, enabling broad distribution and regulatory presence outside the United States. EYLEA and Dupixent have established substantial market penetration across Europe and parts of Asia through these arrangements. The company also participates in international clinical development programs and maintains global regulatory engagement across major pharmaceutical markets.
Leadership & Governance
Regeneron’s leadership structure combines scientific research expertise with long-term operational continuity. Founder leadership has played a central role in shaping the company’s research-driven culture and emphasis on translational science. The company’s strategic vision has consistently emphasized innovation through genetics, rapid biologics development, and long-term investment in internal research capabilities and manufacturing infrastructure.
Key executives include:
- Leonard S. Schleifer – Co-Founder, President, and Chief Executive Officer
- George D. Yancopoulos – Co-Founder, Board Co-Chair, President, and Chief Scientific Officer
- Christopher R. Fenimore – Executive Vice President and Chief Financial Officer
- Marion McCourt – Executive Vice President and Head of Commercial
- Joseph J. LaRosa Jr. – Executive Vice President, General Counsel, and Secretary
- Andrew J. Murphy – Senior Vice President, Research
- Daniel Van Plew – Executive Vice President and General Manager, Industrial Operations and Product Supply
Information regarding leadership structure, operations, partnerships, and business segments has been verified against public disclosures including SEC filings, annual reports, investor presentations, and major financial and industry reporting sources. Where operational details differed between public filings and secondary reporting, priority was given to company regulatory disclosures.